BOUT : Innovator IBD Breakout Opportunities ETF

BOUT is a US Stocks Market Mid-Cap Growth with LOW fees.

BOUT

Innovator IBD Breakout Opportunities ETF

FI Score

30 /100

Diversification Rating

0 /10

Expense Ratio Rating

8 /10

Expense Rating

2 /10

Market Score

0 /10

Category Score

5 /10

Market Size

0 /10

30% FI Score
  • bout
  • ETF
  • US Stocks
  • Mid-Cap Growth

Innovator IBD Breakout Opportunities ETF

Expenses: 0.84% (Better than 1% of similar funds)

This is a bad choice for a Mid-Cap Growth US Stocks fund. See why »

Fund Summary

The investment seeks to track, before fees and expenses, the performance of the IBD® Breakout Stocks Index (the index). The fund will normally invest at least 80% of its net assets (including investment borrowings) in the equity securities that comprise the index. The index seeks to provide opportunistic investment exposure to those stocks with the potential to break out, or experience a period of sustained price growth beyond the stock's recent resistance level, with consideration for various market conditions. The fund is non-diversified.

Largest Holdings

Amount Holding
7.36% PerkinElmer, Inc
7.08% Agilent Technologies, Inc
6.84% Chemed Corporation
6.78% Reynolds Consumer Products Inc
6.13% Monster Beverage Corporation
6.11% Intercontinental Exchange, Inc
6.09% Bio-Rad Laboratories, Inc
6.05% Black Knight, Inc
5.88% Alphabet Inc
5.79% 1Life Healthcare, Inc

Minafi - The intersection of FI, minimalism & mindfulness.

Don't miss out on new posts, courses, interactive articles and more!

Join & Get Your First Course Free

© 2024   Adam Fortuna

Site Map
Triangle Graduation Cap Angle Down Book regular Phone laptop regular fire regular fire regular search regular Acorn duotone Seedling duotone thumbs down duo thumbs up duo